Statistics from Altmetric.com
Because of improved survival of HIV infected patients following the development of effective antiviral drugs and the proven efficacy of interferon/ribavirin in the treatment of hepatitis C in this group of patients,1 gastroenterologists and hepatologists will more and more be involved in the clinical management of such patients. We report an adverse reaction associated with atazanivir, a recently introduced HIV protease inhibitor, which may be relevant for the management of such patients.
Atazanivir is a protease inhibitor with minimal effects on lipid and glucose homeostasis, which is given once daily in combination with other antiretroviral agents.2 This drug is known to cause reversible unconjugated hyperbilirubinaemia by competitive inhibition of the uridine diphosphate-glucuronosyltransferase 1A1 (UGT1A1) in up to 50% of patients treated. In nine per cent of the patients, …